



PRESS RELEASE

BRISTOL-MYERS SQUIBB REACQUIRES RIGHTS TO ASLAN002 (BMS777607) IN ASIA FROM ASLAN

Agreement validates ASLAN's strategy and development capabilities

Singapore, 10 August 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia-prevalent tumour types, today announced that Bristol-Myers Squibb will reacquire the rights to ASLAN002 (BMS777607) in China, Australia, Korea, Taiwan and other Asian territories.

ASLAN002 is a potent small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON immune checkpoint. ASLAN in-licensed ASLAN002 in the above-mentioned markets from Bristol-Myers Squibb in November 2011 and has successfully completed a phase 1 study, in which ASLAN002 was shown to be safe and well tolerated. The phase 1 data demonstrated that inhibition of RON resulted in potent inhibition of plasma biomarkers of RON activity.

ASLAN will receive an upfront payment of US\$10 million and is eligible to receive development and regulatory milestones in excess of US\$50 million. In addition, ASLAN is eligible to receive royalty payments on future world-wide sales of ASLAN002. Bristol-Myers Squibb resumes responsibility for all development and commercialisation activities and expenses.

Commenting on the agreement, Dr Carl Firth, Chief Executive Officer of ASLAN Pharmaceuticals, said: *“The acquisition of ASLAN002 by Bristol-Myers Squibb supports ASLAN’s strategy to in-license investigational programmes and apply the unique development expertise of our team to accelerate the generation of high-quality data and significantly increase the value of a programme. The commercial terms of the agreement further strengthen ASLAN’s financial position following the closing of our recent financing rounds; we are in a very strong position to continue to build our proprietary pipeline of novel clinical programmes.”*

Ends

Media contacts

Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 9107 5559
Email: ASLAN@spurwingcomms.com

About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN’s most advanced



compounds are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002 (partnered with BMS), which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com